Action of brefeldin A on amphibian neurons: passage of newly synthesized proteins through the Golgi complex is not required for continued fast organelle transport in axons.
The relation between the availability of newly synthesized protein and lipid and the axonal transport of optically detectable organelles was examined in peripheral nerve preparations of amphibia (Rana catesbeiana and Xenopus laevis) in which intracellular traffic from the endoplasmic reticulum to the Golgi complex was inhibited with brefeldin A (BFA). Accumulation of fast-transported radio-labeled protein or phospholipid proximal to a sciatic nerve ligature was monitored in vitro in preparations of dorsal root ganglia and sciatic nerve. Organelle transport was examined by computer-enhanced video microscopy of single myelinated axons. BFA reduced the amount of radiolabeled protein and lipid entering the fast-transport system of the axon without affecting either the synthesis or the transport rate of these molecules. The time course of the effect of BFA on axonal transport is consistent with an action at an early step in the intrasomal pathway, and with its action being related to the observed rapid (< 1 h) disassembly of the Golgi complex. At a concentration of BFA that reduced fast-transported protein by > 95%, no effect was observed on the flux or velocity of anterograde or retrograde organelle transport in axons for at least 20 h. Bidirectional axonal transport of organelles was similarly unaffected following suppression of protein synthesis by > 99%. The findings suggest that the anterograde flux of transport organelles is not critically dependent on a supply of newly synthesized membrane precursors. The possibilities are considered that anterograde organelles normally arise from membrane components supplied from a post-Golgi storage pool, as well as from recycled retrograde organelles.
Smith
R S
RS
Department of Anatomy and Cell Biology, University of Alberta, Edmonton, Canada.
Hammerschlag
R
R
Snyder
R E
RE
Chan
H
H
Bobinski
J
J
D000818:Animals; D001370:Axonal Transport; D001369:Axons / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D020126:Brefeldin A; D002794:Choline / Q000378:metabolism; D003517:Cyclopentanes / Q000494:pharmacology*; D019856:Ethanolamine; D004983:Ethanolamines / Q000378:metabolism; D005727:Ganglia, Spinal / Q000378:metabolism / Q000502:physiology*; D006056:Golgi Apparatus / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D007700:Kinetics; D007930:Leucine / Q000378:metabolism; D008854:Microscopy, Electron; D009419:Nerve Tissue Proteins / Q000096:biosynthesis; D009474:Neurons / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D015388:Organelles / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D010525:Peripheral Nerves / Q000378:metabolism / Q000502:physiology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D011892:Rana catesbeiana; D013126:Spinal Nerve Roots / Q000378:metabolism / Q000502:physiology*; D013997:Time Factors; D014316:Tritium; D014982:Xenopus laevis
D003517:Cyclopentanes; D004983:Ethanolamines; D009419:Nerve Tissue Proteins; D011500:Protein Synthesis Inhibitors; D014316:Tritium; D020126:Brefeldin A; D019856:Ethanolamine; D007930:Leucine; D002794:Choline